How Senescent Cells Evade Immune Clearance — and Why It Accelerates Aging

Cellular senescence — the process by which damaged or stressed cells permanently stop dividing — plays a dual role in biology. In the short term, senescence is protective, preventing damaged cells from proliferating and potentially becoming cancerous. Over the long term, however, accumulating senescent cells become a major driver of tissue dysfunction, inflammation, and age-related disease. The key variable is whether the immune system efficiently recognizes and clears these cells.

This review, published in Nature Reviews Immunology by researchers from Cold Spring Harbor Laboratory, Altos Labs, and affiliated institutions, synthesizes current understanding of how the immune system surveys and eliminates senescent cells — and, critically, how senescent cells sometimes evade that surveillance. The authors describe a spectrum of immune evasion strategies that senescent cells employ: recruiting immunosuppressive cell populations to shield themselves, upregulating immune checkpoint molecules (the same class of proteins targeted by cancer immunotherapies like anti-PD-1), and actively suppressing antigen presentation machinery that would otherwise flag them for destruction.

These evasion mechanisms closely parallel the strategies used by tumor cells to escape immune killing — a finding with major therapeutic implications. During aging, the efficiency of immune surveillance declines, meaning senescent cells accumulate at an accelerating rate. This accumulation fuels the chronic low-grade inflammation known as inflammaging, which underlies conditions ranging from cardiovascular disease and neurodegeneration to metabolic dysfunction and cancer.

The authors highlight a critical knowledge gap: most senescence immunology research has focused on a limited set of tissues and immune cell types. Unexplored immune populations and tissue-specific surveillance contexts may hold keys to new interventions.

Therapeutically, modulating immune surveillance of senescent cells — whether by boosting natural clearance mechanisms or deploying engineered immune cells such as senolytic CAR T cells — represents a compelling frontier for extending healthspan and reducing the burden of age-related disease. Restoring immune surveillance may prove as consequential as senolytics that directly kill senescent cells.